TNOX Tanox (MM)

New Data Demonstrate Sustained Viral-Load Reductions, Significant Increases in CD4+ Cell Counts in Treatment-Experienced HIV Patients HOUSTON, May 2 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported 48-week results of its Phase 2 clinical trial of HIV drug candidate, TNX-355. Following previously reported 24-week data, the new results show that HIV-infected patients who received either study dose of TNX-355, in combination with an optimized background regimen (OBR), maintained a considerably greater reduction in viral load than did patients given placebo in combination with OBR. The 48-week results also showed that patients who received TNX-355 with OBR experienced a statistically significant increase in CD4+ cells compared to those who received placebo plus OBR. At 48 weeks, treatment with a 10 milligram-per-kilogram (mg/kg) dose of TNX-355 resulted in a mean viral-load reduction of 0.96 log10, compared with a 0.14 log10 reduction in the placebo group, representing a 0.82 log10 greater reduction (p